Latigo Biotherapeutics filed for an IPO as it prepares to advance non-opioid pain candidates targeting the Nav1.8 channel. The company’s oral small-molecule Nav1.8 inhibitor LTG-001 completed a Phase II study and is set for placebo-controlled Phase III testing for patients undergoing bunion surgery, with additional Phase III work planned across other post-surgical and non-surgical acute pain settings. Latigo said it expects topline results in the second half of 2027 and is also pursuing an open-label Phase III safety study. The filing also outlines a dual program strategy, including LTG-321 for osteoarthritis and follow-on preclinical work (LTG-418) aimed at broader delivery modalities. The company positions LTG-001 to compete with Vertex’s FDA-approved Nav1.8 inhibitor suzetrigine (Journavx), while claiming differentiation needs around efficacy, onset, contraindications, and dose regimen feasibility. Latigo reported about $321.5 million in total funding since founding in 2018.